A private financing roundup highlighted AI platform Chai and radiopharma startup Advancell among the top July raises, as biopharma deal value totaled $7.51 billion across 79 transactions in July—down from June. Through the first seven months of 2026, financing totaled $67.65 billion, the fourth-highest January-through-July figure on record. The reporting also emphasizes which categories are drawing capital: AI-enabled discovery and specialized modalities like radiopharmaceuticals. The funding backdrop matters for pipeline cadence, given that platform-heavy startups often need sustained capital to reach preclinical-to-clinical decision points. While totals softened from June, the mix suggests investors are still prioritizing differentiating technology moats rather than broad “me-too” approaches.